Provident Investment Management Inc. continued to hold its position in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,650 shares of the medical research company’s stock at the end of the second quarter. Provident Investment Management Inc.’s holdings in Amgen were worth $1,164,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Oakworth Capital Inc. boosted its position in Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares in the last quarter. Integrated Wealth Management boosted its position in Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock worth $141,000 after buying an additional 3 shares in the last quarter. Delta Asset Management LLC TN boosted its position in Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares in the last quarter. Capital Advisors Ltd. LLC boosted its position in Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares in the last quarter. Finally, Hanson & Doremus Investment Management boosted its position in Amgen by 3.0% in the second quarter. Hanson & Doremus Investment Management now owns 1,191 shares of the medical research company’s stock worth $181,000 after buying an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 79.18% of the company’s stock.

Shares of Amgen Inc. (NASDAQ:AMGN) traded down 0.36% during mid-day trading on Monday, reaching $172.33. 1,313,441 shares of the company traded hands. The company has a market capitalization of $128.96 billion, a P/E ratio of 17.64 and a beta of 0.87. Amgen Inc. has a 52-week low of $130.09 and a 52-week high of $176.64. The firm’s 50 day moving average price is $171.85 and its 200-day moving average price is $158.72.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The firm earned $5.69 billion during the quarter, compared to the consensus estimate of $5.58 billion. During the same quarter in the previous year, the company posted $2.57 EPS. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Equities analysts predict that Amgen Inc. will post $11.36 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were issued a $1.00 dividend. This represents a $4.00 annualized dividend and a yield of 2.31%. The ex-dividend date was Monday, August 15th. Amgen’s dividend payout ratio (DPR) is 40.90%.

AMGN has been the subject of a number of research analyst reports. Robert W. Baird restated an “outperform” rating and set a $157.00 price objective on shares of Amgen in a research report on Friday, August 26th. Jefferies Group restated a “buy” rating and set a $198.00 price objective on shares of Amgen in a research report on Tuesday, August 23rd. Gabelli began coverage on shares of Amgen in a research report on Friday, August 26th. They set a “hold” rating for the company. Leerink Swann reaffirmed a “hold” rating on shares of Amgen in a report on Sunday, June 26th. Finally, Vetr lowered shares of Amgen from a “strong-buy” rating to a “buy” rating and set a $175.53 target price for the company. in a report on Monday, May 30th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $184.87.

In other Amgen news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is owned by company insiders.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.